Literature DB >> 26207741

Correction: In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis.

Fernanda de Oliveira Demitto, Renata Claro Ribeiro do Amaral, Flaviane Granero Maltempe, Vera Lúcia Dias Siqueira, Regiane Bertin de Lima Scodro, Mariana Aparecida Lopes, Katiany R Caleffi-Ferracioli, Pedro Henrique Canezin, Rosilene Fressatti Cardoso.

Abstract

Entities: Chemical Species

Year: 2015 PMID： 26207741 PMCID： PMC4514749 DOI： 10.1371/journal.pone.0133343

Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240

× No keyword cloud information.

The graph legends for Figs 1 and 2 are incorrect. The symbols for RIF and VP are switched. Please see the complete, correct Figs 1 and 2 here.

Fig 1

Time-kill curve of the Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A exposed to rifampicin (RIF), verapamil (VP), and RIF+VP combination for 7 days at 35–37°C.

Fig 2

Fluorometry assay.

Accumulation of EtBr in the Mycobacterium tuberculosis HRv reference strain and multidrug-resistant clinical isolates 71A, 18, 19, 109, 3614, and 64A. The mycobacteria were loaded with 0.25 μg/ml EtBr in the presence of 0.5 × MIC of verapamil (VP), rifampicin (RIF), and RIF+VP combination for 7 days at 35–37°C.

Fluorometry assay.

1 in total

1. In vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosis.

Authors: Fernanda de Oliveira Demitto; Renata Claro Ribeiro do Amaral; Flaviane Granero Maltempe; Vera Lúcia Dias Siqueira; Regiane Bertin de Lima Scodro; Mariana Aparecida Lopes; Katiany R Caleffi-Ferracioli; Pedro Henrique Canezin; Rosilene Fressatti Cardoso
Journal: PLoS One Date: 2015-02-17 Impact factor: 3.240

1 in total